• Citer

RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors

par Loi, Sherene ;Estrada, Mónica Valeria;Sanchez, Violeta;Sanders, Melinda M.E.;Cook, Rebecca R.S.;Pilkinton, Mark Alexander Lexander M.A.;Mallal, Simon Alexander;Wang, Kai;Miller, Vincent A;Stephens, Philip J;Yelensky, Roman;Dushyanthen, Sathana;Doimi, Franco F.D.;Gomez, Henry;Ryzhov, Sergey S.V.;Darcy, Phillip K;Arteaga, Carlos C.L.;Balko, Justin J.M.;Beavis, Paul P.A.;Salgado, Roberto;Denkert, Carsten;Savas, Peter;Combs, Susan;Rimm, David D.L.;Giltnane, Jennifer J.M.
Référence Clinical cancer research, 22, 6, page (1499-1509)
Publication Publié, 2016-03

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors
Auteur:	Loi, Sherene; Estrada, Mónica Valeria; Sanchez, Violeta; Sanders, Melinda M.E.; Cook, Rebecca R.S.; Pilkinton, Mark Alexander Lexander M.A.; Mallal, Simon Alexander; Wang, Kai; Miller, Vincent A; Stephens, Philip J; Yelensky, Roman; Dushyanthen, Sathana; Doimi, Franco F.D.; Gomez, Henry; Ryzhov, Sergey S.V.; Darcy, Phillip K; Arteaga, Carlos C.L.; Balko, Justin J.M.; Beavis, Paul P.A.; Salgado, Roberto; Denkert, Carsten; Savas, Peter; Combs, Susan; Rimm, David D.L.; Giltnane, Jennifer J.M.
Informations sur la publication:	Clinical cancer research, 22, 6, page (1499-1509)
Statut de publication:	Publié, 2016-03
Sujet CREF:	Cancérologie
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:1078-0432
	info:doi/10.1158/1078-0432.CCR-15-1125
	info:scp/84962301039